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1474Background: Venoarterial extracorporeal membrane oxygenation (VA ECMO) has been used for profound
cardiogenic shock to bridge to decision, ventricular assist device(s) (VADs), or transplant. To assess ventricular
function and volume status along with hemodynamics during ECMO weaning, we developed a standardized
weaning protocol, guided by a miniaturized transesophageal echocardiography probe designed for continuous
hemodynamic monitoring (hemodynamic transesophageal echocardiography [hTEE]). We reviewed our
experience with this weaning protocol with hTEE guidance to assess if we could predict patient outcomes.
Methods:During the academic year of 2011, hTEE-guided ECMOweaning was performed in 21 patients on VA
ECMO. Left and right ventricular function and volume status were assessed by continuous hTEE, while
attempting to wean ECMO after a standardized protocol. The clinical outcomes, management, and positive
predictive value of the device were investigated and analyzed for this cohort of patients.
Results: Of the 21 patients, 6 (29%) had left and right ventricular recovery and underwent optimal medical
therapy or revascularization for underlying coronary artery disease; 7 (33%) had nonrecoverable left and right
ventricular function; and 8 (38%) had right ventricular recovery without improvement of the left ventricular
function. These 8 patients underwent left VAD placement; none subsequently developed profound right
ventricular failure. The positive predictive value for ventricular recovery by hTEE was 100% using our
standardized ECMO weaning protocol (95% confidence interval, 73%-100%).
Conclusions: The hTEE-guided ECMO weaning protocol accurately predicted the ability to wean ECMO to
decision. This protocol can be applied by cardiac intensivists as a part of standard bedside intensive care unit
assessment. (J Thorac Cardiovasc Surg 2013;146:1474-9)Patients presenting with acute cardiogenic shock may
require urgent placement of venoarterial extracorporeal
membrane oxygenation (VA ECMO), before adequate
assessment of either left or right ventricular function. VA
ECMO at full flow provides near-total biventricular support
and decompression of the heart, while allowing time to
recover other end-organ function and to plan further
medical or surgical management. Surgical management
may involve implantable ventricular assist device(s)
(VADs) or heart transplantation.
Determination of the left ventricular (LV) or right
ventricular (RV) function before ECMO weaning is
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The Journal of Thoracic and Cardiovascular Surand possible subsequent left VAD (LVAD) placement. Ideal
candidates for LVAD placement would be those who have
isolated LV failure with reasonably recovered RV function.
Lack of recognition of significant coexisting RV dys-
function may significantly increase the postoperative
morbidity and mortality in those patients transitioned to
LVAD placement, requiring prolonged inotropic agents,
biventricular device support, or extracorporeal support.
Because of the physiologic features of VA ECMO, the
ECMO circuit creates negative pressure and drains venous
blood from the right atrium, preventing determination of
ventricular function from cardiac output or mixed venous
oxygen analysis using a Swan-Ganz catheter (Edwards,
Irvine, Calif). Therefore, intensivists and surgeons have
been looking for alternative methods to assess left and right
ventricular function to make clinical decisions regarding
ECMOweaning and possible subsequent LVAD placement.
A relatively recent tool allowing the intensivist to directly
assess both the contractility and filling status of both the RV
and LV at the bedside in real-time is a miniaturized
hemodynamic transesophageal echocardiography probe
(hTEE; ImaCor, Garden City, NY). Unlike conventional
transesophageal echocardiography (TEE) probes, which
are 10 to 15 mm in diameter and require a TEE-certified
cardiologist to introduce the probe to the patient, thegery c December 2013
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ECMO ¼ extracorporeal membrane oxygenation
hTEE ¼ hemodynamic transesophageal
echocardiography
ICU ¼ intensive care unit
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LVAD ¼ left ventricular assist device
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MhTEE probe is 5.5 mm in diameter, is disposable, and can
remain indwelling for up to 72 hours for cardiac
monitoring.1 The probe can be placed by intensivists with
hTEE training, providing clinically useful information.2-4
The diagnostic yield of hTEE is comparable to that of
conventional TEE regarding biventricular functions and
volume status.2,3,5,6 The safety of TEE was well established,
with a reported incidence of major complications of 0.2%
to 0.5% per insertion.7-10 It is reasonable to expect the
miniaturized hTEE probe to be even safer: we have seen no
major complications in more than 200 hTEE examinations
performed to date in our institution.
The small size and simplicity of the hTEE probe make it
ideal for ECMO weaning because the entire weaning
process may take several hours to observe hemodynamics
after each adjustment of ECMO flow, volume status, and
inotropic support. Motivated by TEE-guided weaning of
cardiopulmonary bypass in the operating room,11 timely
and accurate clinical decisions can be made by the
intensivist for weaning ECMO and subsequent treatment
without additional personnel. We reviewed our experience
using hTEE in patients on ECMO to assess the functional
status of the LV and RV in weaning ECMO before
proceeding to the next level of care.
METHODS
Patients
Between July 2011 and June 2012, 21 consecutive patients (Table 1)
underwent centrally or peripherally cannulated VA ECMO support longer
than 48 hours for multiorgan failure with acute cardiogenic shock, defined
as a rapid decline of hemodynamics requiring multiple inotropes to achieve
a cardiac index of 2 L/min per m2. Once recovered, all patients underwent
hTEE-guided ECMO weaning using our institutional hemodynamic
weaning protocol. Patient demographics, including etiology of shock, are
described in Table 1. This study was approved by the local internal review
board.
ImaCor hTEE Probe
The hTEE probe is a disposable flexible probe with a diameter of
approximately 5.5 mm, similar in size to an oral gastric tube, approved
by the Food and Drug Administration for continuous cardiac functionThe Journal of Thoracic and Carmonitoring over a 72-hour period. The hTEE probe has 15 cm of
penetration at 6.67 MHz (B-mode) and can obtain images revealing left
and right ventricular function and volume status. A midesophageal
4-chamber view was obtained, on average, 42 to 45 cm from the incisors.
A short-axis transgastric viewwas obtained bymanipulating the flexible tip
of the probe using the hand control. Echo parameters obtainable by hTEE
include dimension, area, and ratio measurements in the transgastric
short-axis view and the midesophageal 4-chamber view, in particular, left
ventricular systolic and diastolic area and left ventricular fractional area
change. However, these quantitative values were not routinely recorded
in our practice. Instead, images obtained at hTEE were used directly for
clinical decision making because these qualitative assessments are well
established and validated in hemodynamic management.4 All hTEE
procedures were performed by cardiothoracic surgery intensivists, and
none of them were TEE-trained cardiologists.ECMOWeaning Trial Protocol
Before weaning ECMO, all patients met the criteria of being afebrile
and euvolemic, with resolution of pulmonary edema on x-ray film, with
adequate upper extremity arterial PaO2 and saturation on 50% FiO2 from
both the ECMO and ventilator circuits, and all pre-ECMO end-organ
dysfunction recovered to baseline.
For the weaning trial, anticoagulation was titrated to a partial thrombo-
plastin time target of 60 to 70 seconds to avoid thrombotic complications
while decreasing ECMO flow over the period of assessment. Standard vital
parameters (arterial blood pressure, central venous pressure, heart rate, and
rhythm) were monitored; no Swan-Ganz catheter was inserted during the
weaning process. The hTEE probe was inserted transorally in all
patients. Additional sedation was not required because of the small size
of the probe. The weaning trial consisted of 4 stages:
Stage 1: Baseline LVand RV functions and volume status were assessed
by hTEE on full-flow ECMO support.
Stage 2: After assessment of baseline data, ECMO flow was gradually
decreased in steps of 0.5-L/min increments to the goal of half of the original
flow (stage 2). Throughout the weaning protocol, LV and RV function and
hemodynamic responses (heart rate and blood pressure) were monitored
continuously to allow assessment of ventricular function and volume
status. If, at any period in the weaning protocol, LV or RV distension
occurred or significant hypotension was observed, the weaning trial was
aborted and ECMO support was returned to full flow.
Stage 3: Volume challenges were done with 5% albumin (10 mL/kg)
while ECMO flow was decreased to a minimum flow of 1.2 to
1.5 L/min. This volume challenge was necessary to achieve appropriate
preload. Hemodynamic responses were monitored.
Stage 4: Inotropes (dobutamine and/or milrinone) were started, and the
LV and RV functions and hemodynamics were observed for adequate
response over 1 hour (a fewhours formilrinone). If bothLVandRV functions
were recovered, the patient was considered for definitive ECMO removal. If
LV dysfunction persisted, but RV function was recovered or improved, with
inotropic support, the patient was considered for LVAD placement. If RV
dysfunction persisted, but LV function was recovered, with inotropic sup-
port, the patient was considered for external right VAD placement. If
biventricular dysfunction was observed, repeat assessment or total artificial
heart placementwas considered. If biventricular dysfunctionwas present and
the patientwas not a candidate for support because of another comorbid con-
dition, end-of-life discussionwas considered, because recovery is less likely.
After completion of the weaning trial, the ECMO flow was returned
to full flow and the case was discussed with intensivists, surgeons,
cardiologists, and family members for the timing of surgical intervention.
A Swan-Ganz catheter was not used in any cases in the patients on ECMO
because of a safety issue, such as migration of the catheter or introduction
of the air to the ECMO system, and because of unreliability of the Swan-
Ganz parameters because of the presence of suction applied on the venous
cannula on the ECMO. The weaning processes are summarized in Table 2.diovascular Surgery c Volume 146, Number 6 1475
TABLE 1. Patient demographics
Demographics Value (N ¼ 21)
Male, No. (%) 13 (62)
Age, mean  SD (range), y 49  12 (26-61)
Duration of ECMO, mean  SD (range), d 11.2  6.0 (5-24)
Cannulation site, No. (%)
Peripheral cannulation 19 (91)
Central cannulation 2 (9)
Status at ECMO placement, No. (%)
Salvage procedure 7 (33)
Emergent procedure 6 (29)
Urgent procedure 8 (38)
Etiology of shock, No. (%)
Acutely decompensated cardiomyopathy 10 (48)
Acute myocarditis 3 (14)
Acute myocardial infarction 3 (14)
Postcardiotomy syndrome 2 (9.5)
Pulmonary embolism 1 (4.8)
Pulseless electronic activity code 1 (4.8)
Acute rejection 1 (4.8)
ECMO, Extracorporeal membrane oxygenation, SD, standard deviation.
TABLE 2. VA ECMO weaning protocol using hTEE
Stage Actions
Before weaning Prerequisite: patient is euvolemic and afebrile, chest
x-ray film is clear, and end-organ injury is
resolved. Increase heparinization for PTT goal of
60-70 seconds.
Insert hTEE probe.
Stage 1 Baseline assessment of right and left ventricular
function with full ECMO flow.
Stage 2 Decrease flow from full to half flow in increments of
0.5 L/min and assess LVand RV function by hTEE
over at least 1/2 h after each decrease. If distention
occurs, return to full flow and abort trial.
Stage 3 Volume load (10 mL/kg) over 20 minutes, with half
flow, and assess RVand LV function by hTEE over
at least 1 h.
Stage 4 Load inotrope (dobutamine and/or milrinone),
decrease flow to minimum (1-1.5/min), and assess
LV and RV function at least 1 h.
After weaning
assessment
If biventricular failure persists, consider evaluation
for total artificial heart placement end-of-life
discussion.
If LV dysfunction persists but RV function is
recovered, consider LVAD insertion.
If RV dysfunction persists but LV function is
recovered, consider external RVAD.
If both LV and RV functions are recovered, consider
ECMO decannulation.
After weaning Return to full flow and discuss timing of surgical
intervention.
VA, Venoarterial;ECMO, extracorporealmembrane oxygenation;hTEE, hemodynamic
transesophageal echocardiography;PTT, partial thromboplastin time; LV, left ventricle;
RV, right ventricle; LVAD, left ventricular assist device; RVAD, right ventricular assist
device.
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A total of 7 (33%) of the patients did not tolerate the
initial or subsequent weaning trials, and the procedure
was aborted. These 7 patients remained in severe
biventricular failure regardless of volume or inotropic
challenge and were not candidates for either transplant or
biventricular devices secondary to medical contraindica-
tions: ongoing sepsis (n ¼ 2), documented peri-ECMO
procedure stroke (n¼ 3), and anoxic brain injury and family
wanted to withdraw care (n¼ 1). The weaning protocol was
repeated in 2 to 3 days, and none of the patients
demonstrated adequate cardiac recovery. These patients
were given end-of-life care after discussion with family
and palliative care consultants. The mean length
of ECMO support for these 7 patients was 10.1  6.1
(range, 6-24) days.
A total of 14 (67%) of 21 patients tolerated the full
weaning process (stage 1-4) with hTEE monitoring and
evaluation. A total of 8 (57%) of 14 patients had
recoverable RV function with persistent LV dysfunction
on the basis of the hTEE weaning protocol. All 8 patients
were successfully bridged to LVAD within 1 to 4 days after
the weaning trial. The typical pattern of hTEE findings in
patients who underwent LVAD placement consisted of the
presence of minor contractility of RV in stage 2, minimal
distension of LV and RV on volume challenges (stage 3),
appropriate RV contractility on stage 4, and poor LV
contractility with dilated LV in stage 4. Among these 8
patients who underwent LVAD placement after ECMO
weaning, 4 patients were discharged from the hospital,
giving a survival rate of 50%. Among the nonsurvivors, 3
died from postoperative non–device-related sepsis and1476 The Journal of Thoracic and Cardiovascular Sur1 from perioperative stroke. No patient died fromRV failure
or conditions related to ECMO. The 8 patients who
received LVAD placement were on ECMO for 13.4  6.1
(range, 5-23) days.
A total of 6 (29%) of 14 patients had acceptable LVand
RV recovery by hTEE-guided ECMO weaning. A total of 5
(83%) of these 6 patients were decannulated without
any other intervention. RV recovery was demonstrated in
1 patient who had ongoing reversible LV ischemia. This
patient was able to be weaned off ECMO after conventional
revascularization. One patient had biventricular recovery
from ECMO; however, the patient had sustained an anoxic
brain injury at ECMO cannulation secondary to prolonged
code/hypoxia before ECMO placement. Although the
patient was brain dead, circulation was maintained by
ECMO; thus, the patient was able to donate the liver,
kidney, and other organs. ECMO was discontinued at organ
harvest. One patient was fully recovered from cardiogenic
shock, weaned off ECMO support, and free of the inotropic
support. However, the patient died from arrhythmia-related
cardiac arrest after internal cardiac defibrillator placementgery c December 2013
Cavarocchi et al Perioperative Management
P
Mwhile in-hospital. The mean length of ECMO support of
these 6 patients who had LV and RV recovery was 10.3 
4.3 (range, 5-17) days. Among these 6 patients who had
recovered LV and RV functions, 4 were discharged from
the hospital, giving a survival rate of 67%.
Patterns of the ventricular recovery and failure are shown
in Table 3. The final disposition of all the patients who
underwent the weaning trial is illustrated in Figure 1.
Overall, all 14 patients who passed the hTEE-guided
ECMO weaning trial protocol were successfully weaned
from ECMO, and none of the 7 patients who failed the
weaning trial subsequently regained RVor left function.
The ability of hTEE to detect left or right ventricular
recovery was statistically significant (P < .0001 by
the Fisher exact test). The calculated sensitivity using
2-way contingency table analyses was 100% (95%
confidence interval [CI], 73.2%-100%); specificity, 100%
(95% CI, 56.1%-100%); positive predictive value, 100%
(95% CI, 73.2%-100%); and negative predictive value,
100% (95% CI, 56.1%-100%). There were no hTEE
probe–related complications observed during this study.
DISCUSSION
The management of patients on VA ECMO for
cardiogenic shock is a clinical challenge for the intensivist
regarding exit strategies. In far too many cases, the ‘‘crash-
and-burn’’ (INTERMACS 1) presentation of patients
with viral cardiomyopathy, postmyocardial infarction, or
cardiogenic shock requires urgent placement on VA
ECMO. In that situation, clinicians may not have a clear
knowledge of biventricular function and/or the patient.
This uncertainty presents significant challenges for
management after end-organ and neurologic function
recovery. ECMO can certainly buy time to make a decision,
and a recent review of our ECMO series found ECMO
improved end-organ functions.12
When RV failure exists in the setting of an LVAD
implantation, the perioperative mortality rate increases up
to 19% to 43%.13 Failure to recognize a dysfunctional
RV on transition to an LVAD may result in a protracted
intensive care unit (ICU) course to support a borderline
right ventricle or emergent placement of an RVAD.14TABLE 3. Pattern of ventricular recovery and failure
Stage
Ventricular recovery
Contractility Volum
Stage 1 (baseline) Baseline Decompresse
Stage 2 (half flow) Beginning to respond to
reduced ECMO flow
Adequate vol
ventricle
Stage 3 (volume challenge
and low ECMO flow)
Same as stage 2 or mild
contractility
Adequate res
volume
Stage 4 (inotropes) Adequate contractility Euvolemic
ECMO, Extracorporeal membrane oxygenation.
The Journal of Thoracic and CarThe duration of ECMO support and transition to a VAD
bridge have been poorly defined. Most ECMO centers
perform ECMO weaning without clear guidelines or
algorithms.15 Premature withdrawal from ECMO support
without sufficient RV recovery runs the risk of the scenario
previously described. Unnecessary delays in the weaning
process increase the chance of complications from
prolonged ECMO support and the ICU cost. In addition,
continuing prolonged ECMO support on a patient with no
evidence of any ventricular recovery on repeated weaning
studies and no option for LVAD or biventricular assist
device bridging would not be cost effective and would be
ethically questionable. For patients demonstrating
biventricular failure after repeated attempts at weaning,
families may be able to use this information as guidance
for end-of-life planning.
Conventional determination of cardiac output using the
Swan-Ganz catheter via traditional thermodilution is of
limited value in patients on ECMO.16 Minimally invasive
measurement of cardiac output via pulse contour,
esophageal Doppler, partial carbon dioxide rebreathing,
and thoracic bioimpedance of the thoracic aorta is similarly
not reliable in the setting of VA ECMO.17,18 Serial
mixed venous oxygen saturation assessments require a
Swan-Ganz catheter, and there are always time gaps
between samplings, which do not reflect real-time dynamic
changes of the ventricle during ECMO weaning. Arterial
waveform analyses during the ECMO weaning may be
helpful to determine the ejection of the heart; however, it
does not directly reflect cardiac volume status. No other
technology exists that can be used at the bedside by the
cardiac intensivist for any duration of time and at any
time of day for accurate monitoring of the ECMO patient.19
TEE has been used as a gold standard for cardiac
monitoring in the operating room in patients undergoing
cardiac surgery, in particular for weaning of cardiopulmo-
nary bypass.11,20
In the ICU, the TEE could be an ideal modality for
ECMO weaning because TEE would provide accurate
information for ventricular filling and function. Rastan
and colleagues21 reported more than 500 ECMO cases for
postcardiotomy cardiogenic shock with a relatively shortVentricular failure
e Contractility Volume
d Baseline Decompressed
ume in Same as stage 1 (no response) Mild distension
ponse to Same as stage 1 (no response) Increase distension
(consider termination)
No response to inotropes Distended ventricle
(termination)
diovascular Surgery c Volume 146, Number 6 1477
FIGURE 1. The final disposition of patients on the basis of hemodynamic
transesophageal echocardiography (hTEE) assessment. ECMO, Extracor-
poreal membrane oxygenation; RV, right ventricle; LV, left ventricle;
LVAD, left ventricular assist device; tx, treatment; CABG, coronary artery
bypass grafting; PEA, pulseless electric activity; ICD, internal cardiac
defibrillator.
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Their ECMO weaning was initiated a few days after
ECMO placement, and they evaluated the LV and RV
function by conventional TEE performed a few times a
day.21 Two other groups reported qualitative TEE
assessment in ECMO weaning without specific
protocol.22,23
In a practical hospital setting, TEE services have signi-
ficant limitations regarding their availability because of
the requirement of certified personnel and equipment.19,22
The expense and time commitment from the TEE service
dedicated to full weaning assessment at the bedside would
be difficult. Transthoracic echocardiography (TTE) can be
performed without limitation of personnel; however, the
visualization of the ventricle could be limited by patient
body habitus and/or technician’s ability.7 Furthermore,
both TEE and TTE share the same problem: conventional
TEE and TTE studies represent only a single ‘‘snapshot’’
in time.
Our weaning protocol itself is a bedside analog of
weaning from cardiopulmonary bypass in the operating
room after cardiac surgery, with one key addition:
prolonged time of observation. The hTEE monitoring was
able to accurately reveal the volume response to fluid
challenge and the functional response to inotropes. In the
early period of study, we performed parallel echocardiogra-
phy, and these results were the same as the hTEE; thus,
parallel studies are no longer performed for the ECMO
weaning. The hTEE in our institution was performed by
the qualified cardiac surgery intensivists (N.C.C., H.T.P.,
Q.Y., and H.H.). All images were reviewed by cardiac
surgeons and cardiologists before making final decisions.1478 The Journal of Thoracic and Cardiovascular SurThe hTEE training consisted of didactic education
mannequin training and bedside demonstration of at least
10 cases with experienced individuals.
We, therefore, developed an hTEE-based weaning
protocol to make a real-time assessment of both LV and
RV function throughout the ECMO weaning process.
Furthermore, we chose a qualitative approach, which
involves visual assessment of RV and LV function and
filling, instead of previous quantitative approaches.22,23
The validity of qualitative assessment has been well
established and is readily learned.4,24
The weaning process requires a staged approach with
decreased ECMO support, volume loading, and inotrope
support over 4 to 6 hours. Although such a weaning trial
can be performed in the operating room using conventional
TEE, this is not practical because of time constraints. The
miniaturized hTEE probe offers ease of insertion and
reproducibility of the assessment of both LVand RV volume
status and contractility, and allows continuous monitoring
throughout the weaning trial. The quality and reliability
of the information obtained from hTEE regarding
ventricular function and volume status appears to be
comparable to conventional TEE.5,6 There was excellent
correlation with TTE done at the end of the weaning
process to confirm hTEE findings.
The small size of the hTEE probe may further reduce
complications associated with multiple conventional
TEEs, which are reported to occur 0.2% to 0.5% per
insertion, with an estimated mortality of less than 0.01%
per insertion.7-10 In our limited experience of hTEE over
1 year, we had performed more than 200 studies without
hTEE probe-related complications. Our hTEE-guided
weaning protocol has accurately predicted successful
weaning off ECMO, or bridging from ECMO to LVAD.
In our study, no patients predicted to have a recovered RV
function had any significant right ventricular failure
after LVAD insertion. No patients weaned to medical
management off ECMO on the basis of the weaning trial
protocol required any further mechanical, significant, or
prolonged pharmacologic support. The sensitivity and
specificity of the hTEE for RV recovery were excellent;
however, a larger study is needed to reduce the size of CIs
for positive and negative predictive values.
This study was limited, in part, by the relatively few
patients. Our ECMO program was newly established in
2011; thus, we do not have any data to compare the results
of ECMO weaning using hTEE with other conventional
monitoring methods.
CONCLUSIONS
In our experience with 21 patients weaned from VA
ECMO using the hTEE-based protocol, hTEE accurately
predicted therapeutic outcomes. During this weaning
process, no patient developed complications related to thegery c December 2013
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Mweaning process or hTEE itself. Of those that the hTEE
demonstrated RV recovery, but ongoing LV dysfunction,
all were successfully weaned from ECMO and
underwent LVAD implantation without any significant RV
dysfunction. Of the patients demonstrating biventricular
recovery weaned, they had a reasonable clinical outcome
after ECMO decannulation. In cases of repeated
biventricular failure in attempts at weaning, with significant
comorbidities prohibiting further transplantation or an
implantable biventricular device, families were able to
use the information to help guide their decision to
withdraw. The hTEE-based weaning protocol was simple
and easily reproducible by the intensivist assessing the
patient.
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